THE Therapeutic Goods Administration has added Nucala (mepolizumab) to its list of designated orphan drugs.
The GlaxoSmithKline product is indicated for the treatment of patients with Eosinophilic Granulomatosis with Polyangilitis.
The above article was sent to subscribers in Pharmacy Daily's issue from 22 May 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 22 May 17
